Is Nicotinamide Riboside the Future of COPD Treatment?

In a groundbreaking study, researchers explored the potential of high-dose vitamin B3 to combat inflammation in COPD. The study involved 40 COPD patients who were given either a placebo or a substantial 2 grams of vitamin B3 daily. The results were remarkable! After just 6 weeks, the group receiving vitamin B3 experienced a 53% drop in a key inflammation marker called interleukin-8 (IL-8). Even more impressive, this effect increased to a 63% reduction after 12 weeks. This suggests that vitamin B3 could be a powerful new tool in the fight against COPD.

"Find more on the Ralph Turchiano YouTube channel: @VHFILM (Channel ID: UCSxq36i1g2yb-GdmNq77U7w)"

Disclaimer:
• This information is for educational purposes only and should not be interpreted as medical advice.
• Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, especially if you have a medical condition or are taking medications.
#NR #nicotinamideriboside #COPD #lungdisease #inflammation
Norheim, K.L., Ben Ezra, M., Heckenbach, I. et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging 4, 1772–1781 (2024). https://doi.org/10.1038/s43587-024-00758-1
Chronic obstructive pulmonary disease, COPD, vitamin B3, nicotinamide, niacin, airway inflammation, interleukin-8, IL-8, randomized controlled trial, double-blind study, lung function, FEV1, FVC, high-dose supplementation, oxidative stress, therapeutic intervention, respiratory disease, chronic bronchitis, emphysema, airway remodeling, lung health, inflammatory biomarkers, cytokine, placebo-controlled study, mucus hypersecretion